JP2024525994A5 - - Google Patents
Info
- Publication number
- JP2024525994A5 JP2024525994A5 JP2024527875A JP2024527875A JP2024525994A5 JP 2024525994 A5 JP2024525994 A5 JP 2024525994A5 JP 2024527875 A JP2024527875 A JP 2024527875A JP 2024527875 A JP2024527875 A JP 2024527875A JP 2024525994 A5 JP2024525994 A5 JP 2024525994A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition according
- acid vector
- vector composition
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2110646.3A GB202110646D0 (en) | 2021-07-23 | 2021-07-23 | Nucleic acid vector compositions |
| GB2110646.3 | 2021-07-23 | ||
| PCT/GB2022/051938 WO2023002223A1 (en) | 2021-07-23 | 2022-07-22 | Nucleic acid vector compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525994A JP2024525994A (ja) | 2024-07-12 |
| JP2024525994A5 true JP2024525994A5 (https=) | 2025-07-23 |
Family
ID=77541200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527875A Pending JP2024525994A (ja) | 2021-07-23 | 2022-07-22 | 核酸ベクター組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240327870A1 (https=) |
| EP (1) | EP4351649A1 (https=) |
| JP (1) | JP2024525994A (https=) |
| CN (1) | CN117715659A (https=) |
| GB (1) | GB202110646D0 (https=) |
| MX (1) | MX2024001055A (https=) |
| WO (1) | WO2023002223A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202300914D0 (en) * | 2023-01-20 | 2023-03-08 | Sisaf Ltd | Manufacturing process |
| GB202300915D0 (en) | 2023-01-20 | 2023-03-08 | Sisaf Ltd | mRNA COMPOSITIONS |
| GB202300912D0 (en) * | 2023-01-20 | 2023-03-08 | Sisaf Ltd | Therapeutic compostions and methods |
| GB202402999D0 (en) * | 2024-03-01 | 2024-04-17 | Sisaf Ltd | Medicinal products and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| IT1394656B1 (it) | 2009-07-03 | 2012-07-05 | Brev Angela Srl | Processo per la produzione e l'assemblaggio di una siringa per operazioni medicali |
| CN107614430B (zh) * | 2015-04-17 | 2021-11-23 | 昆士兰大学 | 组合物、粒状材料和用于制造粒状材料的方法 |
| SG11201708681SA (en) * | 2015-04-30 | 2017-11-29 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
| GB201904337D0 (en) * | 2019-03-28 | 2019-05-15 | Sisaf Ltd | A delivery system |
-
2021
- 2021-07-23 GB GBGB2110646.3A patent/GB202110646D0/en not_active Ceased
-
2022
- 2022-07-22 CN CN202280051838.6A patent/CN117715659A/zh active Pending
- 2022-07-22 MX MX2024001055A patent/MX2024001055A/es unknown
- 2022-07-22 JP JP2024527875A patent/JP2024525994A/ja active Pending
- 2022-07-22 US US18/580,636 patent/US20240327870A1/en active Pending
- 2022-07-22 WO PCT/GB2022/051938 patent/WO2023002223A1/en not_active Ceased
- 2022-07-22 EP EP22747739.5A patent/EP4351649A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525994A5 (https=) | ||
| JP7465310B2 (ja) | 多用途性且つ効率的な遺伝子発現のためのｒｎａレプリコン | |
| US20250235525A1 (en) | Influenza vaccine | |
| US20220347307A1 (en) | Messenger rna vaccines and uses thereof | |
| Minigo et al. | Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy | |
| US20220362388A1 (en) | Rna formulations suitable for therapy | |
| JP4535211B2 (ja) | コクリエート送達ビヒクル | |
| JP2006507800A (ja) | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム | |
| CN115944722B (zh) | 一种抗肿瘤mRNA疫苗及其制备方法和应用 | |
| TW202222821A (zh) | 用於預防及/或治療covid-19之組合物及方法 | |
| WO2024044178A1 (en) | Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics | |
| Koppu et al. | Current perspectives and future prospects of mRNA vaccines against viral diseases: a brief review | |
| WO2024055273A1 (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
| WO2024055272A1 (zh) | 能高效表达目的基因的mRNA载体系统、其构建及应用 | |
| CN115927417A (zh) | 无帽线性且无修饰尿苷的mRNA技术平台 | |
| Oğuz et al. | mRNA as a therapeutics: understanding mRNA vaccines | |
| CN117205309A (zh) | 一种流感免疫原组合物和制备方法及其用途 | |
| CN117305328A (zh) | 圆环病毒2型环状rna分子、疫苗的制备及应用 | |
| TW202345870A (zh) | 具有延長半衰期之信使核糖核酸 | |
| CN116925195B (zh) | 一种基于新型冠状病毒的mRNA疫苗 | |
| Borgoyakova et al. | Approaches to improve the immunogenicity of plasmid DNA-based vaccines against COVID-19 | |
| WO2022127820A1 (zh) | 病原样抗原疫苗及其制备方法 | |
| CN113412120A (zh) | 用作治疗性疫苗的自体癌症肿瘤相关染色体外环状dna | |
| WO2024051266A1 (zh) | 用于表达水痘-带状疱疹病毒抗原蛋白的mRNA及其用途 | |
| WO2024261766A1 (en) | Lyophilised vaccine formulation |